Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

被引：15
|
作者：
Garg, Amit [1 ]
Maes, Andrea [1 ]
Corr, Christy [1 ]
Jin, Bo [1 ]
Wadhwa, Tarun [1 ]
Handa, Nikhil [1 ]
Van Dyck, Kristien [1 ]
De Lepeleire, Inge [1 ]
Shah, Jinesh [2 ]
Wagner, John A. [1 ]
Krishna, Rajesh [1 ]
机构：
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Veeda Clin Res, Ahmadabad, Gujarat, India
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 03期
关键词：
Cholesteryl ester transfer protein inhibition; CYP3A; diltiazem; CETP INHIBITOR; DRUG-INTERACTION; BLOOD-PRESSURE; 3A ACTIVITY; MIDAZOLAM;
D O I：
10.1177/0091270010368676
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：436 / 439
页数：4
相关论文
共 50 条
  • [1] Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
    Krishna, Rajesh
    Garg, Amit
    Panebianco, Deborah
    Cote, Josee
    Bergman, Arthur J.
    Van Hoydonck, Pascale
    Laethem, Tine
    Van Dyck, Kristien
    Chen, Jingjing
    Chavez-Eng, Cynthia
    Archer, Laura
    Lutz, Ryan
    Hilliard, Deborah
    Snyder, Karen
    Jin, Bo
    Van Bortel, Luc
    Lasseter, Kenneth C.
    Al-Huniti, Nidal
    Dykstra, Kevin
    Gottesdiener, Keith
    Wagner, John A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (04) : 535 - 545
  • [2] Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
    Krishna, R.
    Bergman, A. J.
    Jin, B.
    Fallon, M.
    Cote, J.
    Van Hoydonck, P.
    Laethem, T.
    Gendrano, I. N., III
    Van Dyck, K.
    Hilliard, D.
    Laterza, O.
    Snyder, K.
    Chavez-Eng, C.
    Lutz, R.
    Chen, J.
    Bloomfield, D. M.
    De Smet, M.
    Van Bortel, L. M.
    Gutierrez, M.
    Al-Huniti, N.
    Dykstra, K.
    Gottesdiener, K. M.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (06) : 679 - 683
  • [3] Anacetrapib, a cholesteryl ester transfer protein inhibitor
    Hooper, Amanda J.
    Burnett, John R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (01) : 103 - 109
  • [4] Assessment of the CYP3A4-mediated drug interaction potential of anacetrapib (ANA), a potent Cholesteryl Ester Transfer Protein (CETP) inhibitor, in healthy subjects
    Krishna, R.
    Bergman, A. J.
    Jin, B.
    Garg, A.
    Roadcap, B.
    Clriou, R.
    Dru, J.
    Cote, J.
    Laethem, T.
    Vets, E.
    Avery, P.
    Gottesdiener, K.
    Wagner, J. A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1105 - 1105
  • [5] Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
    Krishna, Rajesh
    Garg, Amit
    Jin, Bo
    Keshavarz, Sara Sadeghi
    Bieberdorf, Frederick A.
    Chodakewitz, Jeffrey
    Wagner, John A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (05) : 520 - 526
  • [6] Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers
    Krishna, Rajesh
    Bergman, Arthur J.
    Jin, Bo
    Garg, Amit
    Roadcap, Brad
    Chiou, Rita
    Dru, James
    Cote, Josee
    Laethem, Tine
    Wang, Regina W.
    Didolkar, Varsha
    Vets, Eva
    Gottesdiener, Keith
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (01): : 80 - 87
  • [7] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
    Chen, Hanjing
    Chen, Weili
    Li, Hui
    Xu, Hongrong
    Yuan, Fei
    Sheng, Lei
    Liu, Chao
    Lin, Pingping
    Yang, Mengjie
    Li, Xuening
    Liu, Yang
    Walker, Brittany Marie
    Gheyas, Ferdous
    Iwamoto, Marian
    Stoch, S. Aubrey
    Krishna, Rajesh
    ADVANCES IN THERAPY, 2021, 38 (07) : 3973 - 3985
  • [8] Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects
    Hanjing Chen
    Weili Chen
    Hui Li
    Hongrong Xu
    Fei Yuan
    Lei Sheng
    Chao Liu
    Pingping Lin
    Mengjie Yang
    Xuening Li
    Yang Liu
    Brittany Marie Walker
    Ferdous Gheyas
    Marian Iwamoto
    S. Aubrey Stoch
    Rajesh Krishna
    Advances in Therapy, 2021, 38 : 3973 - 3985
  • [9] EFFECTS OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR ANACETRAPIB ON LIPOPROTEIN SUBFRACTIONS
    Krauss, R.
    Wojnoonski, K.
    Geaney, J. C.
    Kimberlin, R.
    Johnson-Levonas, A.
    Luk, J.
    Krishna, R.
    Wagner, J.
    Anderson, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [10] Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys
    Tan, Eugene Y.
    Hartmann, Georgy
    Chen, Qing
    Pereira, Antonio
    Bradley, Scott
    Doss, George
    Zhang, Andy Shiqiang
    Ho, Jonathan Z.
    Braun, Matthew P.
    Dean, Dennis C.
    Tang, Wei
    Kumar, Sanjeev
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (03) : 459 - 473
12345